The proportion of patients with diabetes who initiated insulin treatment during follow-up was lower in the sacubitril/valsartan group than in the valsartan group, but the difference did not reach statistical significance (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62–1.02, P = 0.07). This evidence concerns the gene INS and diabetes mellitus.